TL;DR - Teledyne Technologies (NYSE: TDY) agreed to acquire Varex Imaging (NASDAQ: VREX) for $18.90 per share in an all-cash deal valued at approximately $1.1 billion, including net debt - The offer represents a 52.3% premium over Varex's Friday (Aug. 8) closing price of $12.41; VREX surged 48% in premarket trading - Teledyne fills a critical product gap: it makes X-ray detectors but has no presence in high-radiation oncology detectors or X-ray tubes — both core Varex segments - Deal expected to close in early 2027, pending regulatory approval and a Varex shareholder vote - Sidoti downgraded VREX to Hold at a $19 price target, effectively validating the deal price
Part A — Deal Overview
Teledyne Technologies announced on August 10, 2026 a definitive merger agreement to acquire all outstanding shares of Varex Imaging Corporation for $18.90 per share in cash. The aggregate transaction value is approximately $1.1 billion, which includes equity awards and Varex's net debt as of April 3, 2026.
The offer represents a 52.3% premium over Varex's August 8 closing price of $12.41, and an approximate 88–89% premium over Varex's late-May 2026 trading level near $10 per share, when the stock was weighed down by tariff uncertainty and operating losses.
Both boards of directors unanimously approved the transaction. The deal is structured as a merger requiring a Varex stockholder vote and customary regulatory clearances. Closing is expected in early 2027.
The Companies
Teledyne Technologies (NYSE: TDY) is a diversified technology company with four segments: Digital Imaging, Instrumentation, Aerospace & Defense Electronics, and Engineered Systems. For fiscal year 2025, Teledyne reported revenue of $6.1 billion (+7.9% year-over-year) and GAAP net income of $894.8 million ($18.88 diluted EPS). Market capitalization is approximately $20 billion.
Varex Imaging (NASDAQ: VREX) is a Salt Lake City-based manufacturer of X-ray imaging components — tubes, digital detectors, high-voltage interconnects, and image-processing software — serving medical diagnostic, industrial inspection, security, and non-destructive testing markets. The company employs approximately 2,500 people across North America, Europe, and Asia. In its fiscal year ended October 3, 2025, Varex reported revenue of $844.6 million (+4.1% year-over-year) but a net loss of $70.3 million, widening 44% from fiscal 2024.
Advisory Teams
Evercore served as financial advisor to Varex; Orrick, Herrington & Sutcliffe LLP was legal counsel. Latham & Watkins LLP and McGuireWoods LLP advised Teledyne.
Part B — Investor Analysis
Why Teledyne Wants Varex — and Why Now
Teledyne Executive Chairman Robert Mehrabian described the rationale in plain terms: "Our products are uniquely complementary with minimal overlap." The specifics matter for investors.
Teledyne already manufactures X-ray detectors, but its product line stops short of two high-value niches that Varex owns:
| Product Category | Teledyne Before Deal | Varex Adds |
|---|---|---|
| X-ray tubes (radiography, fluoroscopy, CT) | None | Core offering |
| High-radiation environment detectors (oncology) | None | Core offering |
| Photon-counting CT detectors | Limited | Advanced capability |
| Standard X-ray flat-panel detectors | ✓ | Additional scale |
The most strategically significant item is photon-counting computed tomography (PCCT). Traditional CT scanners use energy-integrating detectors that average photon counts; photon-counting detectors distinguish individual X-ray photon energies, enabling higher resolution, lower radiation dose, and better tissue contrast. Major scanner OEMs — Siemens Healthineers, GE HealthCare, Philips — are actively transitioning their premium CT lines to PCCT. Varex is a key component supplier to that transition.
By acquiring Varex now, Teledyne secures a supply-chain position in a technology that is moving from clinical trials to mass-market rollout. Waiting until the technology matures would mean buying at a far higher multiple.
Deal Valuation: Cheap by Medical-Imaging Standards
At $1.1 billion for a business generating $845 million in revenue, Teledyne is paying roughly 1.3x EV/Revenue. For context, diversified medical-device companies with similar imaging exposure typically trade between 2x and 4x revenue. The discounted entry reflects Varex's current unprofitability — its fiscal 2025 net loss of $70.3 million was driven by elevated operating costs and a tariff-related inventory writedown.
A notable caveat: Varex's third quarter of fiscal 2025 benefited from a non-recurring $10 million tariff refund, which flatters the underlying revenue trend. Investors should note that the $845 million top line includes approximately $10 million of one-time benefit.
For Teledyne, the acquisition adds roughly 14% to its annual revenue base, though it initially dilutes margins given Varex's loss-making status. Management has not disclosed specific synergy targets, but the "minimal overlap" framing signals that cost-side synergies may be limited — the value thesis is primarily revenue expansion and technology access, not rationalization.
Market Reaction and Deal Arbitrage
Varex shares surged 48.3% in premarket trading on August 11, moving from $12.41 to approximately $18.40 — just $0.50 below the offer price. That narrow $0.50 deal spread (2.7%) implies the market gives the deal a high probability of closing on stated terms. Mergers blocked at this stage by regulators are rare for industrial technology companies without significant antitrust overlap.
Sidoti, which covers Varex, downgraded shares to Hold and set a $19 price target on August 10 — essentially stamping the offer as fair and discouraging speculation on a sweetened bid.
Risks Worth Monitoring
Regulatory timeline: While no obvious competition concerns exist (Teledyne does not compete directly with Varex in X-ray tubes or oncology detectors), certain markets — particularly Chinese government procurement of medical imaging equipment — could require SAMR review, potentially extending the timeline.
Integration execution: Varex has operated as an independent public company since 2017 (spun out of Varian Medical). Teledyne's acquisition track record is strong (FLIR in 2021 was its largest deal at $8 billion), but integrating a $845M-revenue component supplier adds meaningful complexity.
Tariff exposure: Varex sources components from multiple countries. Should IEEPA tariffs be extended or broadened, input cost pressure could widen losses before Teledyne can drive operational improvements.
Varex shareholder vote: Given the 52% premium and no competing bid on the horizon, rejection is unlikely — but the vote adds a procedural hurdle before early 2027 closing.
The Bottom Line for TDY Investors
For Teledyne shareholders, the acquisition is a calculated bet on the PCCT technology transition in medical imaging. The 1.3x EV/Revenue entry price is attractive by sector standards, though the path to profitability for the acquired entity will require execution. Teledyne's $6.1 billion revenue base means the $1.1 billion deal is digestible, and the company's history of disciplined M&A — including the transformative FLIR integration — provides a reasonable basis for optimism.
For Varex shareholders, the 52.3% premium over a stock that was trading near $10 as recently as May 2026 represents a clean exit at a price that far exceeds what the business can currently support on public markets. The deal locks in that value against the risk of further tariff-related volatility.
This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities.
Sources: - Teledyne to Acquire Varex Imaging Corporation — Varex Press Release - Teledyne 8-K Filing (SEC EDGAR) - Varex Imaging (VREX) Rises 48% After Teledyne Bid - Teledyne to Acquire Varex Imaging — Yahoo Finance - Varex FY2025 Earnings — Varex Imaging
